Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 185

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer

Vandekerkhove, Gillian, Struss, Werner J., Annala, Matti, Kallio, Heini M.L., Khalaf, Daniel, Warner, Evan W., Herberts, Cameron, Ritch, Elie, Beja, Kevin, Loktionova, Yulia, Hurtado-Coll, Antonio, Fazli, Ladan, So, Alan, Black, Peter C., Nykter, Matti, Tammela, Teuvo, Chi, Kim N., Gleave, Martin E., Wyatt, Alexander W. · 2019 · European Urology

Abstract

BACKGROUND Several systemic therapeutic options exist for metastatic castrate-sensitive prostate cancer (mCSPC). Circulating tumor DNA (ctDNA) can molecularly profile metastatic castration-resistant prostate cancer and can influence decision-making, but remains untested in mCSPC. OBJECTIVE To determine ctDNA abundance at de novo mCSPC diagnosis and whether ctDNA provides complementary clinically relevant information to a prostate biopsy. DESIGN, SETTING, AND PARTICIPANTS We collected plasma cell-free DNA (cfDNA) from 53 patients newly diagnosed with mCSPC and, where possible, during treatment. Targeted sequencing was performed on cfDNA and DNA from diagnostic prostate tissue. RESULTS AND LIMITATIONS The median ctDNA fraction was 11% (range 0-84%) among untreated patients but was lower (1.0%, range 0-51%) among patients after short-term (median 22d) androgen deprivation therapy (ADT). TP53 mutations and DNA repair defects were identified in 47% and 21% of the cohort, respectively. The concordance for mutation detection in matched samples was 80%. Combined ctDNA and tissue analysis identified potential driver alterations in 94% of patients, whereas ctDNA or prostate biopsy alone was insufficient in 19 cases (36%). Limitations include the use of a narrow gene panel and undersampling of primary disease by prostate biopsy. CONCLUSIONS ctDNA provides additional information to a prostate biopsy in men with de novo mCSPC, but ADT rapidly reduces ctDNA availability. Primary tissue and ctDNA share relevant somatic alterations, suggesting that either is suitable for molecular subtyping in de novo mCSPC. The optimal approach for biomarker development should utilize both a tissue and liquid biopsy at diagnosis, as neither captures clinically relevant somatic alterations in all patients. PATIENT SUMMARY In men with advanced prostate cancer, tumor DNA shed into the bloodstream can be measured via a blood test. The information from this test provides complementary information to a prostate needle biopsy and could be used to guide management strategies. Sequencing data were deposited in the European Genome-phenome Archive (EGA) under study identifier EGAS00001003351.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2018.12.042

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 185

Metadata

Authors
Vandekerkhove, G., Struss, W. J., Annala, M., Kallio, H. M. L., Khalaf, D., Warner, E. W., Herberts, C., Ritch, E., Beja, K., Loktionova, Y., Hurtado-Coll, A., Fazli, L., So, A., Black, P. C., Nykter, M., Tammela, T., Chi, K. N., Gleave, M. E., & Wyatt, A. W.
Venue
European Urology
Publisher
Elsevier BV
Published
2019-04
Volume
75
Issue
4
Pages
667-675
ISSN
0302-2838 (ISSN-L)
OpenAlex
W2909626878
Cited by
185
References
5
FWCI
17.95
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. https://app.cochat.ai/papers/10.1016/j.eururo.2018.12.042
The paper
Vandekerkhove, G., Struss, W. J., Annala, M., Kallio, H. M. L., Khalaf, D., Warner, E. W., Herberts, C., Ritch, E., Beja, K., Loktionova, Y., Hurtado-Coll, A., Fazli, L., So, A., Black, P. C., Nykter, M., Tammela, T., Chi, K. N., Gleave, M. E., & Wyatt, A. W. (2019). Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. European Urology. https://doi.org/10.1016/j.eururo.2018.12.042

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.